Get the latest news source for local headlines from Nebraska Note. Covering politics, education, crime, health and more.

Generalized Myasthenia Gravis Treatment Market to Reach US$11.1 Billion by 2035 | FDA Approval of Klygefa Adds a Convenience-Led Competitive Dimension

Nov 17, 2026

AChR-Positive Patients Represent About 80% of the Generalized Myasthenia Gravis Treatment Opportunity. New U.S. authorization sharpens competition around treatment delivery, while Japan’s existing approval shifts attention to local adoption and market access.

-- November 17, 2026 - The global generalized myasthenia gravis (gMG) treatment market was valued at US$6.4 billion in 2025 and is projected to reach US$11.1 billion by 2035, growing at a 5.8% CAGR during 2026-2035. Serotype coverage, speed and durability of response, dosing frequency, safety monitoring and reimbursement will shape commercial differentiation as choices multiply.

The U.S. Food and Drug Administration’s approval of Klygefa (gefurulimab) for adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) introduces a new competitive variable into a treatment market increasingly shaped by targeted mechanisms and treatment experience. The approval adds a once-weekly, subcutaneous, self-administered autoinjector option to the U.S. landscape, with potential implications for treatment selection, patient preference, care delivery, and brand differentiation.

Request Executive Sample: https://www.datamintelligence.com/download-sample/generalized-myasthenia-gravis-treatment-market

The FDA decision was based on results from the pivotal PREVAIL Phase III trial. At week 26, Klygefa met the primary endpoint, with a statistically significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score versus placebo (treatment difference: -1.6; 95% CI: -2.4 to -0.8; p<0.0001). AstraZeneca reported that clinical improvement was observed as early as week one and sustained through one year. The company describes Klygefa as the first and only approved dual-binding nanobody C5 inhibitor in the United States.

The approval comes as gMG treatment moves beyond broad immunosuppression toward therapies directed at FcRn, complement, and B-cell pathways. DataM Intelligence estimates the global gMG treatment market at US$6.4 billion in 2025, with a projection of US$11.1 billion by 2035. North America is the largest regional market, while Asia-Pacific is projected to grow fastest. The market outlook reflects rising targeted-therapy adoption, more mechanism-based choices, and competition over response, durability, safety, patient eligibility, and treatment burden.

Competitive Developments Shaping the Market

Recent regulatory, clinical, and pipeline developments point to an intensifying contest for differentiation:

  • Klygefa’s U.S. approval: The authorization brings a weekly self-injection format to U.S. adults with AChR-positive gMG, expanding treatment choice within complement inhibition.
  • Klygefa’s European Union approval: The EU authorized the therapy as an add-on to standard treatment for adults with AChR-positive gMG, extending its regulatory footprint.
  • New Klygefa data: At the 2026 AANEM and MGFA meetings, Alexion presented findings across 15 abstracts, including long-term PREVAIL results and analyses of hospitalization and rescue-therapy use.
  • IMAAVY evidence generation: Johnson & Johnson presented new gMG findings at the same 2026 meetings, underscoring continued competition from FcRn-targeting therapies.
  • Pediatric gMG review: In October 2026, argenx reported that the FDA accepted its supplemental application for VYVGART and VYVGART Hytrulo in pediatric gMG for priority review.
  • Cemdisiran regulatory review: Regeneron announced in June 2026 that the FDA and EMA accepted its regulatory submissions for a subcutaneous C5-targeting therapy, adding a late-stage competitor to monitor.
  • Next-generation pipeline activity: Dianthus initiated a Phase III trial of claseprubart in June, while Vor Bio completed enrollment in its global Phase III telitacicept study in September.

Taken together, these developments make convenience one competitive dimension among several. The commercial question is how administration frequency and setting interact with efficacy evidence, durability, safety, eligibility, payer requirements, and physician preference. These developments do not establish comparative clinical superiority among therapies.

United States: launch execution and access become the next tests

For U.S. decision-makers, FDA approval moves the focus from regulatory differentiation to launch execution. Commercial performance will depend on how specialists position Klygefa among available targeted treatments, how payers assess its clinical and economic value, and whether patients and providers view weekly self-administration as a meaningful fit for individual care plans. The approval applies to adults who are AChR-antibody positive; it should not be interpreted as covering all serological groups.

AstraZeneca estimates that approximately 98,500 people in the United States are diagnosed with gMG, including about 81,000 who are AChR-positive. These figures indicate the potential scale of the labeled population, but diagnosis estimates do not equal immediately addressable demand. Diagnosis rates, treatment eligibility, payer coverage, physician choice, and patient preference will influence uptake.

Japan: established approval, distinct market questions

Japan presents a different strategic lens. AstraZeneca reports Klygefa is already approved in Japan and other markets. The U.S. decision therefore does not represent a pending Japanese regulatory milestone. For Japan-focused executives, relevant questions include local access and reimbursement conditions, specialist familiarity, uptake across treatment pathways, and how the product fits into regional portfolio planning.

The global report identifies Asia-Pacific as the fastest-growing region but does not establish Japan-specific growth or market share. Companies should assess Japanese opportunities with country-level evidence, including patient identification, treatment practice, access, and the competitive mix. Avoiding assumptions based on U.S. approval or regional growth projections will be essential to sound resource allocation.

Purchase This Exclusive Report: https://www.datamintelligence.com/buy-now-page?report=generalized-myasthenia-gravis-treatment-market&from=report

Additional Benefits:

 ✅ Get Interactive Dashboard Access (With No Additional Cost)

 ✅ Three months of analyst support to answer queries related to the report.

Strategic implications for biopharma leaders

Klygefa’s U.S. authorization raises the bar for product differentiation in a market where mechanism alone may not determine commercial position. Portfolio leaders should evaluate convenience alongside clinical durability, serological reach, treatment sequencing, safety monitoring, and access economics. Competitors will need to track whether self-administration changes treatment-setting preferences and whether physicians view administration flexibility as an advantage for specific patient profiles.

For investors and corporate strategy teams, the approval reinforces the need to examine both near-term competition and longer-horizon pipeline threats, including extended-interval complement inhibition and therapies targeting broader immune pathways. For market-access leaders, the critical evidence base will include real-world utilization, persistence, resource use, and payer outcomes as they emerge. These are evaluation priorities, not conclusions established by the approval itself.

Company Profiles

AstraZeneca/Alexion now has Klygefa, a dual-binding C5 inhibitor, approved in the U.S., EU and Japan for specified adult AChR-positive gMG populations. Its once-weekly subcutaneous autoinjector offers a different delivery profile from infusion-based complement treatment. Commercial uptake will depend on access, safety monitoring and differentiation within a competitive class.

Argenx markets VYVGART and VYVGART Hytrulo, FcRn-targeted therapies with intravenous and subcutaneous presentations. The U.S. label expansion to all adult gMG patients regardless of antibody status broadens the potential treatment population and makes real-world sequencing and reimbursement central to continued growth.

Johnson & Johnson commercializes IMAAVY (nipocalimab), an FcRn blocker approved in the U.S. for eligible adult and pediatric patients with AChR- or MuSK-positive gMG. Its 2026 longer-term data updates support continued evaluation of durability, while the company’s wider gMG evidence program may help define its role across patient groups.

UCB competes with RYSTIGGO (rozanolixizumab), an FcRn inhibitor, and ZILBRYSQ (zilucoplan), a C5 inhibitor. The proposed prefilled pen for zilucoplan shows the company is pursuing delivery-device differentiation alongside established therapies; regulatory status and market availability vary by geography.

Contact Info:
Name: Sai Kiran
Email: Send Email
Organization: DataM Intelligence 4Market Research LLP
Address: 2243 Rocoso TRL, Leander TX 78641
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com/

Release ID: 89209912

If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release that require attention or if there is a need for a press release takedown, we kindly request that you notify us without delay at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or guide you through the removal process. Ensuring accurate and reliable information is fundamental to our mission.